Adjuvant chemotherapy stands as a vital ally in the battle against cancer, employed post-primary treatments to eliminate residual cancer cells and thwart potential recurrence. Its pivotal role lies in targeting minuscule disease remnants undetectable through conventional means, effectively reducing the likelihood of metastasis or relapse. Customized to each patient's cancer type and stage, this supplementary therapy significantly bolsters survival rates. However, its efficacy is tempered by notable side effects like nausea and fatigue, prompting the ongoing pursuit of tailored treatment approaches that optimize outcomes while mitigating adverse reactions. As research strides forward, refining adjuvant chemotherapy protocols remains pivotal, ensuring that each dose strikes the delicate balance between efficacy and preserving patients' quality of life.



Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States